Search clinical trials for: MGMT promoter-methylated glioblastoma

Total 2019 results

Vastra Gotaland Region
Karolinska Institutet; Oslo University Hospital; Aarhus University Hospital; Sahlgrenska... and other collaborators

Not yet recruiting

Lomustine in Addition to Standard of Care in Patients With MGMT Methylated Glioblastoma

Glioblastoma, IDH-wildtype | MGMT-Methylated Glioblastoma
Ivy Brain Tumor Center
GlaxoSmithKline

Not yet recruiting

A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma

Glioblastoma | Brain Tumor | GBM | Brain Neoplasms, Adult, Malignant
Shuttle Pharmaceuticals, Inc.

Not yet recruiting

Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter

Glioblastoma, IDH-wildtype

United States
Hideho Okada, MD, PhD
National Cancer Institute (NCI); California Institute for Regenerative Medicine...

Recruiting

Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells

Glioblastoma | Recurrent Glioblastoma | EGFR Gene Mutation | MGMT-Unmethylated Glioblastoma

United States
Zhongnan Hospital

Not yet recruiting

Cisplatin Plus Temozolomide Compared With Temozolomide in Patients With MGMT Promotor Unmethylated Glioblastoma (Glioblastoma)

Glioblastoma Multiforme of Brain
Istituto Oncologico Veneto IRCCS
Bayer S.p.A

Recruiting

Regorafenib With Temozolomide With or Without RT in MGMT-Methylated, IDH Wild-type GBM Patients (REGOMA-2)

Glioblastoma, IDH-wildtype | MGMT-Methylated Glioblastoma

Italy
Cantex Pharmaceuticals
Medpace, Inc.

Recruiting

Azeliragon in MGMT Unmethylated Glioblastoma

Glioblastoma

United States
Sheba Medical Center
Prof. Ronit Satchi-Fainaro, Director, Cancer Biology Research Center, Tel...

Recruiting

Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases (14)

Advanced Glioblastoma | MGMT-Unmethylated Glioblastoma | Metastatic Melanoma in the Central Nervous System

Israel
Northwestern University
National Cancer Institute (NCI); Moleculin Biotech, Inc.

Not yet recruiting

WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

MGMT-Unmethylated Glioblastoma | Glioblastoma, IDH-Wildtype

United States
Washington University School of Medicine
Incyte Corporation; PapiVax Biotech, Inc.

Recruiting

Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma

Unmethylated Glioblastoma

United States
Novartis Pharmaceuticals

Recruiting

Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma

Newly Diagnosed and Recurrent Glioblastoma

Spain, Israel, Portugal
Darell Bigner
Rockefeller University

Recruiting

D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients

Newly Diagnosed MGMT Unmethylated Glioblastoma

United States
Zhongnan Hospital

Not yet recruiting

Etoposide Plus Cisplatin Compared With Temozolomide in Patients With Glioblastoma

MGMT-Unmethylated Glioblastoma
TVAX Biomedical
FDA Office of Orphan Products Development

Recruiting

Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM)

Glioblastoma Multiforme of Brain

United States
Northwestern University
National Cancer Institute (NCI)

Recruiting

Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of Glioblastoma

Glioblastoma | Astrocytoma | Recurrent Glioblastoma | MGMT-Unmethylated Glioblastoma | Glioblastoma, IDH-Wildtype

United States
Novartis Pharmaceuticals

Recruiting

A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.

Glioblastoma

Spain, Switzerland, France, Portugal, United States
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine®) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma

Glioblastoma | Gliosarcoma

United States
Leland Metheny
National Cancer Institute (NCI)

Recruiting

hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM) (hSTAR GBM)

Glioblastoma Multiforme | Supratentorial Gliosarcoma | Glioblastoma Multiforme, Adult | Supratentorial Glioblastoma

United States
The Affiliated Nanjing Drum Tower Hospital of Nanjing...
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Study of AK105 With Anlotinib and Radiotherapy Adjuvant Therapy in MGMT Unmethylated Newly Diagnosed Glioblastoma.

MGMT-Unmethylated Glioblastoma

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

Anlotinib Combined With STUPP for MGMT Nonmethylated Glioblastoma

MGMT-Unmethylated Glioblastoma

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Peposertib and Radiation Therapy, Followed by Temozolomide for the Treatment of Patients With Newly Diagnosed MGMT Unmethylated Glioblastoma or Gliosarcoma

Glioblastoma | Gliosarcoma

United States
Marco G Paggi, MD, PhD
Istituto Oncologico Veneto IRCCS; Regina Elena Cancer Institute; Carlo Besta...

Recruiting

Repurposing Chlorpromazine in the Treatment of Glioblastoma (RACTAC)

Glioblastoma Multiforme | MGMT-Unmethylated Glioblastoma

Italy
Global Coalition for Adaptive Research
Bayer; Kazia Therapeutics Limited; Biohaven Pharmaceuticals, Inc.; Kintara Therapeutics... and other collaborators

Recruiting

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma (GBM AGILE)

Glioblastoma

United States, France, Germany, Canada, Australia, Switzerland
Genenta Science

Recruiting

A Study Evaluating Temferon in Patients With Glioblastoma & Unmethylated MGMT (TEM-GBM)

Glioblastoma Multiforme

Italy
Haukeland University Hospital
University of Oslo; Oslo University Hospital; University Hospital of North Norway and other collaborators

Recruiting

Bortezomib and Temozolomide in Recurrent Grade-4 Glioma Unmethylated MGMT Promoter (BORTEM-17) (BORTEM-17)

Glioblastoma

Norway
National Cancer Institute (NCI)

Recruiting

Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer

Glioblastoma | Gliosarcoma | Recurrent Glioblastoma | MGMT-Unmethylated Glioblastoma

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma

Gliosarcoma | MGMT-Unmethylated Glioblastoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Tinostamustine With or Without Radiation Therapy in Treating Patients With Newly Diagnosed MGMT-Unmethylated Glioblastoma

Glioblastoma | Gliosarcoma | MGMT-Unmethylated Glioblastoma

United States
National Cancer Institute (NCI)

Suspended

Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment

Recurrent Glioblastoma, IDH-Wildtype | MGMT-Methylated Glioblastoma | Recurrent MGMT-Methylated Glioblastoma

United States
CureVac

Active, not recruiting

Safety and Tolerability of CVGBM in Adults With Newly Diagnosed MGMT-Unmethylated Glioblastoma or Astrocytoma

Glioblastoma

Belgium, Germany, Netherlands
Kazia Therapeutics Limited

Completed

Safety, Pharmacokinetics and Efficacy of Paxalisib (GDC-0084) in Newly-diagnosed Glioblastoma

Glioblastoma, Adult

United States
Kintara Therapeutics, Inc.

Active, not recruiting

Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent Setting

Glioma | Glioblastoma | Brain Cancer | Glioblastoma Multiforme | GBM

United States
Kintara Therapeutics, Inc.
Sun Yat-sen University

Active, not recruiting

Safety Study of VAL-083 and Radiotherapy in Patients With Newly Diagnosed GBM Having Unmethylated MGMT Expression

Glioma | Glioblastoma | Brain Cancer | Glioblastoma Multiforme | GBM

China
University Hospital Heidelberg
German Cancer Research Center; National Center for Tumor Diseases, Heidelberg; German Cancer Aid

Completed

NCT Neuro Master Match - N²M² (NOA-20) (N²M²)

Glioblastoma, Adult

Germany
Memorial Sloan Kettering Cancer Center

Active, not recruiting

Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma

Glioblastoma

United States
TME Pharma AG

Active, not recruiting

Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients (GLORIA)

Glioblastoma

Germany
European Organisation for Research and Treatment...
Amgen

Withdrawn

Phase II Trial of Romiplostim for Thrombocytopenia Induced by Lomustine at First Progression of MGMT Promoter-meth Glioblastoma (RIGOLETTO)

First Progression of MGMT Promoter-methylated Glioblastoma

Spain, Switzerland
Stanton Gerson MD
National Cancer Institute (NCI)

Completed

BG & TMZ Therapy of Glioblastoma Multiforme

Glioblastoma Multiforme

United States
Institut Cancerologie de l'Ouest
Hospices Civils de Lyon; Centre Antoine Lacassagne

Terminated

Phase-1 Study of Folinic Acid to Modulate MGMT Gene in Glioblastoma (FOLAGLI)

Glioblastoma | Grade IV Astrocytoma

France
Basilea Pharmaceutica
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Terminated

Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

Glioblastoma | MGMT-Unmethylated Glioblastoma

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...

Withdrawn

6 Months Adjuvant Temozolomide (TMZ) vs No Adjuvant TMZ in Newly Diagnosed MGMT Methylated Glioblastoma (GBM)

MGMT-Methylated Glioblastoma
NYU Langone Health

Completed

Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma

GBM | MGMT-unmethylated Glioblastoma (GBM)

United States
Brown University
University of California, San Diego; Milton S. Hershey Medical Center; University... and other collaborators

Completed

PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation

Glioblastoma Multiforme

United States
Tocagen Inc.

Terminated

A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)

Melanoma | Sarcoma | Lymphoma | Head and Neck Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Bladder Cancer | Triple Negative Breast Cancer | IDH1 Mutated Solid Tumors | IDH1 Mutated or MGMT Methylated Recurrent HGG (Not Recruiting)

United States
University Hospital, Bonn

Completed

Efficacy and Safety Study of Lomustine/Temozolomide Combination Therapy vs. Standard Therapy for Glioblastoma Patients (CeTeG)

Glioblastoma

Germany
Bassam Abdulkarim
Pfizer; Canadian Cancer Society (CCS)

Unknown

Combining Sunitinib, Temozolomide and Radiation to Treat Patients Diagnosed With Glioblastoma

Glioblastoma Multiforme

Canada
AHS Cancer Control Alberta

Withdrawn

Combining Radiotherapy and Temozolomide With Dichloroacetate in Patients With Newly Diagnosed Glioblastoma

Glioblastoma
Center Eugene Marquis
Rennes University Hospital

Completed

Comparison of Different Methods to Test MGMT Status in Glioblastoma Patients (ECOM)

Glioblastoma

France
Children's Hospital Medical Center, Cincinnati

Terminated

Treatment of Newly Diagnosed Brain Tumors With Chemotherapy and Radiation Using Cells Modified for Chemoprotection and an Experimental Drug to Decrease the Tumor Cell Resistance to Chemotherapy

Glioblastoma Multiforme (WHO Grade IV) | Anaplastic Astrocytoma (WHO Grade III)

United States
Bart Neyns

Terminated

Effect of Radiation Therapy Plus Temozolomide Combined With Cilengitide or Cetuximab on the 1-year Overall Survival of Patients With Newly Diagnosed MGMT-promoter Unmethylated Glioblastoma

Glioblastoma

Belgium

Search clinical trials for: MGMT promoter-methylated glioblastoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations